An Open-Label, Single-Arm, Multicenter Study, of Combination Anti-CD3/CD7 Immunotoxin (T-Guard) for Steroid-Refractory Acute Graft-versus-Host Disease)

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 07 Dec 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Anti-CD3-ricin chain A conjugate/anti-CD7-ricin chain A conjugate (Primary)
Indications Graft-versus-host disease
Focus Registrational; Therapeutic Use
Sponsors Xenikos

25 Aug 2020 Status changed from suspended to discontinued. Reason the study was stopped: Initiated a new randomized trial per discussion with FDA
18 Mar 2020 Status changed from recruiting to suspended. Reason the status is suspended because the study has reached its halting criteria.
18 Dec 2019 According to a Xenikos media release, the first patient has been treated.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com